Anna Halpern, MD
Associate Professor
Clinical Research Division, Fred Hutch
The focus of Dr. Anna Halpern’s research and patient care is hematologic, or blood, cancers. She develops and tests evidence-based, tailored therapies for adult patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms. Dr. Halpern designs and conducts clinical trials of new treatments and care strategies, and she uses large databases to study broad-scale issues such as risk factors for treatment toxicity. Her goal is to improve outcomes for patients with these diseases.
Other Appointments & Affiliations
Clinical Director for Leukemia and Myeloid Malignancies, Fred HutchClinical Director for Leukemia and Myeloid Malignancies
Fred Hutch
Associate Professor, Division of Hematology and Oncology
Department of Medicine, University of Washington School of Medicine
Education
Hematology-Oncology Fellowship, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, 06/2013-01/2017
Internal Medicine Internship and Residency, University of Chicago Medical Center, Chicago, IL, 06/2009-06/2012
MD, Brown Medical School, Providence, RI, 08/2005-05/2009
AB, Magna Cum Laude, Brown University, Providence, RI, 08/2001-05/2005
Clinical Expertise
Myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and acute myeloid leukemia (AML)